Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(4 years from now) | |
US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(4 years from now) | |
US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(6 years from now) | |
US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(4 years from now) | |
US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(5 years from now) | |
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(5 years from now) | |
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(5 years from now) | |
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(6 years from now) | |
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(7 years from now) | |
US8575135 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
US8921341 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
US8940718 (Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(9 years from now) | |
US9757406 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
US11707479 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
US10086011 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(9 years from now) | |
US11116783 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
US10086011 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
US11707479 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) | |
US9757406 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-293) | Mar 19, 2027 |
M(M-264) | Jul 14, 2023 |
Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
M(M-277) | Apr 27, 2025 |
Pediatric Exclusivity(PED) | Dec 10, 2028 |
New Dosing Schedule(D-177) | Nov 15, 2022 |
New Patient Population(NPP) | Mar 19, 2023 |
New Chemical Entity Exclusivity(NCE) | Jun 28, 2021 |
New Strength(NS) | Mar 19, 2023 |
NCE-1 date: 11 December, 2027
Market Authorisation Date: 19 March, 2020
Treatment: For the treatment of hepatitis c
Dosage: TABLET;ORAL; PELLETS;ORAL